| Vimal Sarup, MD | |
|
1309 E Ridge Rd Ste 1, Mcallen, TX 78503-1518 | |
| (956) 631-8875 | |
| (956) 683-1502 |
| Full Name | Vimal Sarup |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 1309 E Ridge Rd Ste 1, Mcallen, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073837787 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | T9976 (Texas) | Primary |
| Entity Name | Valley Retina Institute P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225139942 PECOS PAC ID: 7113903659 Enrollment ID: O20040625000871 |
News Archive
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, CEO, has been invited to present at EmTech, the Emerging Technologies Conference hosted by MIT and produced by MIT's Technology Review magazine. The conference will take place September 22nd - 24th on the MIT campus in Cambridge, MA.
Investigators at the Vall d´Hebron University Hospital and the Vall d'Hebron Institute of Oncology (VHIO), have participated in an international phase III study, published in The New England Journal of Medicine.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, Rhei Pharmaceuticals HK Ltd., received regulatory and marketing approval for MuGard in China from the State Food and Drug Administration, or SFDA, to treat oral mucositis in cancer patients.
Bcl-2-like protein 11 (BIM) deletion in advanced non-small cell lung cancer (NSCLC) is associated with shorter progression free survival (PFS) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or chemotherapy treated Asian patients.
Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced a strategic partnership between the company's contract research organization, Caliper Discovery Alliances & Services (CDAS), and Prestwick Chemical (Strasbourg, France) to provide customized outsourced medicinal chemistry and in vitro and in vivo preclinical biology programs for drug discovery research.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vimal Sarup, MD Po Box 4830, Edinburg, TX 78540-4830 Ph: (956) 631-8875 | Vimal Sarup, MD 1309 E Ridge Rd Ste 1, Mcallen, TX 78503-1518 Ph: (956) 631-8875 |
News Archive
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, CEO, has been invited to present at EmTech, the Emerging Technologies Conference hosted by MIT and produced by MIT's Technology Review magazine. The conference will take place September 22nd - 24th on the MIT campus in Cambridge, MA.
Investigators at the Vall d´Hebron University Hospital and the Vall d'Hebron Institute of Oncology (VHIO), have participated in an international phase III study, published in The New England Journal of Medicine.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, Rhei Pharmaceuticals HK Ltd., received regulatory and marketing approval for MuGard in China from the State Food and Drug Administration, or SFDA, to treat oral mucositis in cancer patients.
Bcl-2-like protein 11 (BIM) deletion in advanced non-small cell lung cancer (NSCLC) is associated with shorter progression free survival (PFS) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or chemotherapy treated Asian patients.
Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced a strategic partnership between the company's contract research organization, Caliper Discovery Alliances & Services (CDAS), and Prestwick Chemical (Strasbourg, France) to provide customized outsourced medicinal chemistry and in vitro and in vivo preclinical biology programs for drug discovery research.
› Verified 9 days ago
Dr. Rachel Ann Gelman, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 5201 N G St, Mcallen, TX 78504 Phone: 956-305-5795 Fax: 956-618-4639 | |
Dr. Raul Adrian Pena, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1400 E Ridge Rd Ste 10, Mcallen, TX 78503 Phone: 956-661-8733 Fax: 956-661-8724 | |
Dr. Melissa Ixcamey, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1309 E Ridge Rd Ste 1, Mcallen, TX 78503 Phone: 956-844-6440 | |
Cooper M Clark, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1309 E Ridge Rd, Suite 1, Mcallen, TX 78503 Phone: 956-631-8875 Fax: 956-682-6280 | |
Dr. Wade Alan Graham, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1400 E Ridge Rd Ste 3, Mcallen, TX 78503 Phone: 956-429-4900 Fax: 956-429-4901 | |
Dr. Nehal Rashmikant Patel, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1309 East Ridge Road, Suite 1, Mcallen, TX 78503 Phone: 956-631-8875 Fax: 956-631-9134 |